SUNRISES研究:舒尼替尼与依维莫司交替方案对比序贯方案一线治疗转移性肾癌的随机II期研究
SUNRISES是一项随机开放标签II期研究,比较舒尼替尼与依维莫司交替周期方案与标准序贯方案(舒尼替尼进展后换用依维莫司)一线治疗透明细胞型转移性肾细胞癌的疗效。研究因新一代疗法出现而提前终止,仅入组41例(计划102例),1年无进展生存率交替组49.7% vs 对照组84.62%(P=0.11),主要终点未达到。结论提示交替使用mTOR抑制剂未能预防VEGFR阻断耐药。
要点
- 交替方案未改善1年PFS率,对照组数值更高但差异未达统计学显著。
- 交替组≥3级不良事件有减少趋势(50% vs 73.3%,P=0.14)。
- 研究提前终止,样本量小,结论需谨慎解读。
核心结论
- 交替使用舒尼替尼与依维莫司未能预防VEGFR阻断耐药,主要终点未达到。
研究设计与样本
- 随机开放标签II期研究,计划入组102例,实际入组41例,按2:1随机分配至实验组(26例)和对照组(15例)。
- 纳入初治透明细胞型转移性肾细胞癌患者,实验组接受舒尼替尼12周后依维莫司12周交替治疗,对照组为标准序贯治疗(舒尼替尼进展后换用依维莫司)。
- 主要终点为1年无进展生存率,次要终点包括中位PFS、总生存、缓解率和安全性。
主要发现
- 1年PFS率实验组49.7% vs 对照组84.62%(P=0.11)。
- ≥3级不良事件实验组50% vs 对照组73.3%(P=0.14)。
- 两组中位总生存相似,其他次要终点倾向对照组。
局限性
- 因新一代疗法出现,入组缓慢,研究提前终止,样本量仅41例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy of alternating cycles of sunitinib and everolimus vs standard sequential treatment of sunitinib followed by everolimus in first-line metastatic renal cell carcinoma (mRCC), as alternating blockade of vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin (mTOR) pathways could potentially prevent the occurrence of resistance to anti-VEGFR therapy in mRCC. PATIENTS AND METHODS: SUNRISES, a randomised open-label Phase II study, investigated the efficacy of alternating cycles of sunitinib and everolimus vs standard sequential treatment of sunitinib followed by everolimus upon progression. Treatment-naïve patients with clear-cell mRCC were included. Alternating treatment consisted on 12 weeks of sunitinib, followed by 12 weeks of everolimus. The primary endpoint was the progression-free survival (PFS) rate at 1 year. The secondary endpoints included the median PFS, overall survival (OS), response rate, and safety. RESULTS: Accrual was low due to the advent of new-generation therapies, and the study was stopped prematurely. Only 41 patients out of the planned 102 patients were accrued, and randomised in a 2:1 ratio (15 patients to the control arm, 26 to the experimental arm). In all, 60.9% of patients had performance status (PS) 0 and 39% PS 1; 63% had a favourable prognostic risk profile, while 36% were intermediate risk. The primary endpoint was not met. The 1-year PFS rate was 49.7% (experimental arm) vs 84.62% (control arm; P = 0.11). There was a trend towards fewer Grade ≥3 adverse events with the alternating approach (50% vs 73.3%; P = 0.14). The median OS was similar in both treatment arms. The other secondary endpoints favoured the control arm. CONCLUSIONS: The study failed to show any benefit of alternating cycles of sunitinib and everolimus in patients with mRCC. The alternating approach using an mTOR inhibitor does not seem to prevent the occurrence of resistance to VEGFR blockade.
引用
- Rodriguez-Vida A, Bamias A, Esteban E, et al. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). BJU Int. 2020. PMID: 32654362. doi:10.1111/bju.15165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。